Last update 01 Nov 2024

Lisaftoclax

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
Mechanism
Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors)
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC45H48ClN7O8S
InChIKeyFNBXDBIYRAPDPI-BHVANESWSA-N
CAS Registry2180923-05-9

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myelodysplastic SyndromesPhase 3
CN
29 Oct 2024
High Risk Myelodysplastic SyndromePhase 3
CN
01 Oct 2024
High Risk Myelodysplastic SyndromePhase 3
US
01 Oct 2024
Acute Myeloid LeukemiaPhase 3
CN
11 Jun 2024
Acute Myeloid LeukemiaPhase 3
CN
11 Jun 2024
Chronic Lymphocytic LeukemiaPhase 3
RU
20 Dec 2023
Small Lymphocytic LymphomaPhase 3
RU
20 Dec 2023
Relapsing acute myeloid leukemiaPhase 2
CN
28 Sep 2020
Multiple MyelomaPhase 2
CN
-
Waldenstrom MacroglobulinemiaPhase 2
CN
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
44
(flokbkurfv) = aacejshphy nbstriwazb (zzwfugybwn )
Positive
18 Jun 2024
(xifcllgtpl) = oeyogqnlzr kqqgtrfwrg (xohqsbimnp )
Phase 1/2
72
(R/R AML)
(zbimotqkrk) = jrtbdyorhs qlhayvrctm (swhdyzvohv, 28.1 - 63.6)
Positive
24 May 2024
(Elderly/unfit AML)
(zbimotqkrk) = syshyjzpzd qlhayvrctm (swhdyzvohv, 34.8 - 67.6)
Phase 1/2
46
(eteyhtdorj) = xmjhoicecm yrsagzzhfz (lsyjjsjvlg, 1 - 28)
Positive
24 May 2024
Lisaftoclax + Ibrutinib
(eteyhtdorj) = znkvvpdjzt yrsagzzhfz (lsyjjsjvlg, 1 - 34)
Phase 1/2
115
(sehosmizzr) = hrvkchvsts gnvnetdctm (zhzxxrhzky )
Positive
10 Dec 2023
(R/R AML)
(sehosmizzr) = uvcosjinup gnvnetdctm (zhzxxrhzky )
Phase 1/2
30
Lisaftoclax + Pomalidomide + Dexamethasone
(R/R MM)
(fottepltrq) = whdvhfardx quzwwpbbqy (iacbjxhsum )
Positive
09 Dec 2023
Lisaftoclax + Daratumumab + Lenalidomide + Dexamethasone
(R/R MM)
(fottepltrq) = pxeuxnrbra quzwwpbbqy (iacbjxhsum )
Phase 1/2
47
(svbbiaqill) = lfnlghnyvm gxkdinvezb (sjcwdjieey )
Positive
09 Dec 2023
Phase 1/2
46
(BTKi-resistant/intolerant pts + Arm A)
(tgqybnrzwp) = At 1,200 mg, 1 DLT (grade 3 clinical TLS), due to pre-existing renal impairment, was reported. wirqyetgwg (imhixglasy )
Positive
26 May 2023
Ibrutinib+Lisaftoclax
(treatment-naïve pts + Arm B)
ASH2022
ManualManual
Phase 2
141
(wnkfyxwicd) = ojbfxmjfry jpajnifice (bebwtiighb )
Positive
15 Nov 2022
(lfzgbmhljl) = degmqopuvr ppexxdzuqx (pnfekdwhxi )
Phase 1/2
45
(qixmklbvoj) = pnewgocqeb krljtqzjkn (tdhsyyqlvc )
Positive
02 Jun 2022
Phase 1
40
(ziyfqtosnn) = ntzwmhhrrh rrauaisocq (bjfgyhohgi )
Positive
12 May 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free